Japan Approves World’s First iPS Stem-Cell Therapies for Parkinson’s and Heart Failure

What is the Announcement?

Japan has approved ground-breaking stem-cell therapies for treating Parkinson's disease and severe heart failure, making them the world’s first commercially approved medical treatments using iPS cells.

Parkinson’s Treatment – Amchepry:

Pharmaceutical company Sumitomo Pharma received approval to manufacture and sell Amchepry, a therapy that:

Transplants stem cells into a patient’s brain

Helps replace dopamine-producing neurons lost in Parkinson’s disease.

The treatment uses induced pluripotent stem (iPS) cells derived from healthy donors.

Heart Failure Treatment – ReHeart:

Japan’s health ministry also approved ReHeart, developed by medical startup Cuorips.

ReHeart works by:

Using heart muscle cell sheets

Helping form new blood vessels

Improving heart function in severe heart failure patients.

What are iPS Cells?

Induced Pluripotent Stem (iPS) cells are created by reprogramming mature adult cells back into a stem-cell state.

These cells can:

Develop into any type of cell in the human body

Be used for regenerative medicine and disease treatment.

The technology avoids the use of embryos.

Nobel Prize Connection:

Japanese scientist Shinya Yamanaka won the Nobel Prize in Physiology or Medicine in 2012 for discovering iPS cells.

Clinical Trial Findings

A study conducted by Kyoto University showed:

7 Parkinson’s patients participated in the trial

Each received 5–10 million stem cells implanted in the brain

Patients were monitored for two years

No major side effects were observed

4 patients showed improvement in symptoms.

Conditional Approval System:

Japan granted “conditional and time-limited approval”, meaning:

The treatment can reach patients faster

Data from smaller clinical trials can be used initially

Further monitoring will continue after approval.